CA2110159A1 - Technique permettant de prevenir les fausses reactions dans les tests immunologiques - Google Patents

Technique permettant de prevenir les fausses reactions dans les tests immunologiques

Info

Publication number: CA2110159A1
Authority: CA; Canada
Prior art keywords: body fluid; sample; chemical compound; temperature; antigen
Prior art date: 1992-03-26
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

CA 2110159

Other languages

English (en)

Inventor

Jacques Singer

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Montefiore Medical Center

Original Assignee

Individual

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-03-26

Filing date

1993-03-26

Publication date

1993-09-30

1993-03-26 Application filed by Individual filed Critical Individual

1993-09-30 Publication of CA2110159A1 publication Critical patent/CA2110159A1/fr

Status Abandoned legal-status Critical Current

Links

238000000034 method Methods 0.000 title claims abstract description 147
230000002265 prevention Effects 0.000 title claims abstract description 9
238000012360 testing method Methods 0.000 title abstract description 77
238000006243 chemical reaction Methods 0.000 title abstract description 47
230000001900 immune effect Effects 0.000 title abstract description 4
210000001124 body fluid Anatomy 0.000 claims abstract description 86
239000010839 body fluid Substances 0.000 claims abstract description 86
150000003839 salts Chemical class 0.000 claims abstract description 67
230000007935 neutral effect Effects 0.000 claims abstract description 44
238000010438 heat treatment Methods 0.000 claims abstract description 29
239000004816 latex Substances 0.000 claims description 117
229920000126 latex Polymers 0.000 claims description 116
239000000427 antigen Substances 0.000 claims description 85
102000036639 antigens Human genes 0.000 claims description 85
108091007433 antigens Proteins 0.000 claims description 85
239000002245 particle Substances 0.000 claims description 79
239000000523 sample Substances 0.000 claims description 72
210000002966 serum Anatomy 0.000 claims description 65
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 claims description 60
108060003951 Immunoglobulin Proteins 0.000 claims description 55
102000018358 immunoglobulin Human genes 0.000 claims description 54
150000001875 compounds Chemical class 0.000 claims description 51
238000003018 immunoassay Methods 0.000 claims description 51
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 43
239000000872 buffer Substances 0.000 claims description 39
239000004471 Glycine Substances 0.000 claims description 30
238000001514 detection method Methods 0.000 claims description 30
230000004520 agglutination Effects 0.000 claims description 24
239000011780 sodium chloride Substances 0.000 claims description 24
239000003153 chemical reaction reagent Substances 0.000 claims description 22
DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 claims description 20
230000000694 effects Effects 0.000 claims description 19
230000009257 reactivity Effects 0.000 claims description 18
238000005189 flocculation Methods 0.000 claims description 17
230000016615 flocculation Effects 0.000 claims description 17
239000000203 mixture Substances 0.000 claims description 17
DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 claims description 15
-1 organic acid salt Chemical class 0.000 claims description 13
229940072221 immunoglobulins Drugs 0.000 claims description 12
239000012470 diluted sample Substances 0.000 claims description 11
230000015572 biosynthetic process Effects 0.000 claims description 9
239000013043 chemical agent Substances 0.000 claims description 8
230000008030 elimination Effects 0.000 claims description 7
238000003379 elimination reaction Methods 0.000 claims description 7
238000001556 precipitation Methods 0.000 claims description 7
UEUXEKPTXMALOB-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O UEUXEKPTXMALOB-UHFFFAOYSA-J 0.000 claims description 7
230000003612 virological effect Effects 0.000 claims description 7
229920001817 Agar Polymers 0.000 claims description 6
230000002452 interceptive effect Effects 0.000 claims description 6
230000000415 inactivating effect Effects 0.000 claims description 5
239000001103 potassium chloride Substances 0.000 claims description 4
235000011164 potassium chloride Nutrition 0.000 claims description 4
239000002775 capsule Substances 0.000 claims description 3
235000018417 cysteine Nutrition 0.000 claims description 3
XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 claims description 3
XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 claims description 2
VHJLVAABSRFDPM-ZXZARUISSA-N dithioerythritol Chemical compound SC[C@H](O)[C@H](O)CS VHJLVAABSRFDPM-ZXZARUISSA-N 0.000 claims description 2
230000008569 process Effects 0.000 claims description 2
238000012817 gel-diffusion technique Methods 0.000 claims 3
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims 2
102000014447 Complement C1q Human genes 0.000 claims 1
108010078043 Complement C1q Proteins 0.000 claims 1
238000007865 diluting Methods 0.000 claims 1
238000012216 screening Methods 0.000 abstract description 11
230000002779 inactivation Effects 0.000 abstract description 8
108010074605 gamma-Globulins Proteins 0.000 description 38
238000003556 assay Methods 0.000 description 34
239000000243 solution Substances 0.000 description 31
230000027455 binding Effects 0.000 description 24
235000018102 proteins Nutrition 0.000 description 24
102000004169 proteins and genes Human genes 0.000 description 24
108090000623 proteins and genes Proteins 0.000 description 24
210000004027 cell Anatomy 0.000 description 23
238000004220 aggregation Methods 0.000 description 21
238000010790 dilution Methods 0.000 description 21
239000012895 dilution Substances 0.000 description 21
230000002776 aggregation Effects 0.000 description 19
230000000295 complement effect Effects 0.000 description 19
239000011734 sodium Substances 0.000 description 18
239000012530 fluid Substances 0.000 description 16
238000002474 experimental method Methods 0.000 description 11
239000012634 fragment Substances 0.000 description 11
238000002360 preparation method Methods 0.000 description 11
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 10
230000007246 mechanism Effects 0.000 description 10
239000000126 substance Substances 0.000 description 10
241001337994 Cryptococcus <scale insect> Species 0.000 description 9
241001465754 Metazoa Species 0.000 description 9
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
210000004369 blood Anatomy 0.000 description 8
239000008280 blood Substances 0.000 description 8
239000000725 suspension Substances 0.000 description 8
201000007336 Cryptococcosis Diseases 0.000 description 7
102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 7
108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 7
241000700605 Viruses Species 0.000 description 7
230000005540 biological transmission Effects 0.000 description 7
201000010099 disease Diseases 0.000 description 7
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
241000221204 Cryptococcus neoformans Species 0.000 description 6
241001494479 Pecora Species 0.000 description 6
238000012092 latex agglutination test Methods 0.000 description 6
229920002521 macromolecule Polymers 0.000 description 6
229920001282 polysaccharide Polymers 0.000 description 6
239000005017 polysaccharide Substances 0.000 description 6
102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 5
108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 5
241000283973 Oryctolagus cuniculus Species 0.000 description 5
239000012491 analyte Substances 0.000 description 5
238000004458 analytical method Methods 0.000 description 5
230000001580 bacterial effect Effects 0.000 description 5
239000000440 bentonite Substances 0.000 description 5
229910000278 bentonite Inorganic materials 0.000 description 5
SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 5
230000008859 change Effects 0.000 description 5
150000004676 glycans Chemical class 0.000 description 5
239000003112 inhibitor Substances 0.000 description 5
206010039073 rheumatoid arthritis Diseases 0.000 description 5
230000035945 sensitivity Effects 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
102000006395 Globulins Human genes 0.000 description 4
108010044091 Globulins Proteins 0.000 description 4
230000000890 antigenic effect Effects 0.000 description 4
210000001175 cerebrospinal fluid Anatomy 0.000 description 4
239000003610 charcoal Substances 0.000 description 4
238000009792 diffusion process Methods 0.000 description 4
230000005764 inhibitory process Effects 0.000 description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 4
230000003287 optical effect Effects 0.000 description 4
244000045947 parasite Species 0.000 description 4
230000004044 response Effects 0.000 description 4
230000000405 serological effect Effects 0.000 description 4
239000007787 solid Substances 0.000 description 4
239000007790 solid phase Substances 0.000 description 4
238000003756 stirring Methods 0.000 description 4
239000006228 supernatant Substances 0.000 description 4
210000001519 tissue Anatomy 0.000 description 4
210000002700 urine Anatomy 0.000 description 4
108010074051 C-Reactive Protein Proteins 0.000 description 3
102100032752 C-reactive protein Human genes 0.000 description 3
241000283707 Capra Species 0.000 description 3
102000016917 Complement C1 Human genes 0.000 description 3
108010028774 Complement C1 Proteins 0.000 description 3
102000004190 Enzymes Human genes 0.000 description 3
108090000790 Enzymes Proteins 0.000 description 3
HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000699670 Mus sp. Species 0.000 description 3
108090000526 Papain Proteins 0.000 description 3
239000004365 Protease Substances 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
241000194017 Streptococcus Species 0.000 description 3
206010053614 Type III immune complex mediated reaction Diseases 0.000 description 3
239000012190 activator Substances 0.000 description 3
239000000969 carrier Substances 0.000 description 3
238000010494 dissociation reaction Methods 0.000 description 3
230000005593 dissociations Effects 0.000 description 3
239000012153 distilled water Substances 0.000 description 3
229940088598 enzyme Drugs 0.000 description 3
230000002538 fungal effect Effects 0.000 description 3
239000011521 glass Substances 0.000 description 3
229960002897 heparin Drugs 0.000 description 3
229920000669 heparin Polymers 0.000 description 3
208000006454 hepatitis Diseases 0.000 description 3
239000001257 hydrogen Substances 0.000 description 3
229910052739 hydrogen Inorganic materials 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000016178 immune complex formation Effects 0.000 description 3
230000002401 inhibitory effect Effects 0.000 description 3
230000003993 interaction Effects 0.000 description 3
150000002500 ions Chemical class 0.000 description 3
238000005259 measurement Methods 0.000 description 3
229940055729 papain Drugs 0.000 description 3
235000019834 papain Nutrition 0.000 description 3
239000000123 paper Substances 0.000 description 3
238000005375 photometry Methods 0.000 description 3
239000000376 reactant Substances 0.000 description 3
238000004062 sedimentation Methods 0.000 description 3
FVAUCKIRQBBSSJ-UHFFFAOYSA-M sodium iodide Chemical compound [Na+].[I-] FVAUCKIRQBBSSJ-UHFFFAOYSA-M 0.000 description 3
208000006379 syphilis Diseases 0.000 description 3
208000035143 Bacterial infection Diseases 0.000 description 2
241000283690 Bos taurus Species 0.000 description 2
108091003079 Bovine Serum Albumin Proteins 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
108010022366 Carcinoembryonic Antigen Proteins 0.000 description 2
102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
241000223205 Coccidioides immitis Species 0.000 description 2
102000055157 Complement C1 Inhibitor Human genes 0.000 description 2
108700040183 Complement C1 Inhibitor Proteins 0.000 description 2
108010028780 Complement C3 Proteins 0.000 description 2
102000016918 Complement C3 Human genes 0.000 description 2
108010091326 Cryoglobulins Proteins 0.000 description 2
OJLOPKGSLYJEMD-LNQMSSPSSA-N Cyotec Chemical compound CCCCC(C)(O)CC=C[C@H]1[C@H](O)CC(=O)[C@@H]1CCCCCCC(=O)OC OJLOPKGSLYJEMD-LNQMSSPSSA-N 0.000 description 2
241000701022 Cytomegalovirus Species 0.000 description 2
108020004414 DNA Proteins 0.000 description 2
RWSOTUBLDIXVET-UHFFFAOYSA-N Dihydrogen sulfide Chemical class S RWSOTUBLDIXVET-UHFFFAOYSA-N 0.000 description 2
241000588724 Escherichia coli Species 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
201000006353 Filariasis Diseases 0.000 description 2
241000233866 Fungi Species 0.000 description 2
102000003886 Glycoproteins Human genes 0.000 description 2
108090000288 Glycoproteins Proteins 0.000 description 2
241000606768 Haemophilus influenzae Species 0.000 description 2
NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
241000282412 Homo Species 0.000 description 2
206010020751 Hypersensitivity Diseases 0.000 description 2
206010024229 Leprosy Diseases 0.000 description 2
241000588653 Neisseria Species 0.000 description 2
206010028980 Neoplasm Diseases 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
102000004576 Placental Lactogen Human genes 0.000 description 2
108010003044 Placental Lactogen Proteins 0.000 description 2
239000000381 Placental Lactogen Substances 0.000 description 2
239000004793 Polystyrene Substances 0.000 description 2
108010059712 Pronase Proteins 0.000 description 2
241000702670 Rotavirus Species 0.000 description 2
241000607142 Salmonella Species 0.000 description 2
229920002684 Sepharose Polymers 0.000 description 2
PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
241000191967 Staphylococcus aureus Species 0.000 description 2
ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
241000243777 Trichinella spiralis Species 0.000 description 2
241000607479 Yersinia pestis Species 0.000 description 2
238000010521 absorption reaction Methods 0.000 description 2
239000003463 adsorbent Substances 0.000 description 2
230000004523 agglutinating effect Effects 0.000 description 2
208000026935 allergic disease Diseases 0.000 description 2
230000007815 allergy Effects 0.000 description 2
102000013529 alpha-Fetoproteins Human genes 0.000 description 2
108010026331 alpha-Fetoproteins Proteins 0.000 description 2
230000004075 alteration Effects 0.000 description 2
229960004821 amikacin Drugs 0.000 description 2
LKCWBDHBTVXHDL-RMDFUYIESA-N amikacin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O1)O)NC(=O)[C@@H](O)CCN)[C@H]1O[C@H](CN)[C@@H](O)[C@H](O)[C@H]1O LKCWBDHBTVXHDL-RMDFUYIESA-N 0.000 description 2
230000000592 anti-cryptococcal effect Effects 0.000 description 2
238000000149 argon plasma sintering Methods 0.000 description 2
208000022362 bacterial infectious disease Diseases 0.000 description 2
229940125717 barbiturate Drugs 0.000 description 2
230000000903 blocking effect Effects 0.000 description 2
238000009835 boiling Methods 0.000 description 2
239000007853 buffer solution Substances 0.000 description 2
229940095731 candida albicans Drugs 0.000 description 2
229940099378 cytotec Drugs 0.000 description 2
238000011161 development Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
230000029087 digestion Effects 0.000 description 2
239000006185 dispersion Substances 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000006862 enzymatic digestion Effects 0.000 description 2
PROQIPRRNZUXQM-ZXXIGWHRSA-N estriol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H]([C@H](O)C4)O)[C@@H]4[C@@H]3CCC2=C1 PROQIPRRNZUXQM-ZXXIGWHRSA-N 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
229940047650 haemophilus influenzae Drugs 0.000 description 2
231100000283 hepatitis Toxicity 0.000 description 2
239000005556 hormone Substances 0.000 description 2
229940088597 hormone Drugs 0.000 description 2
JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
125000004435 hydrogen atom Chemical class [H]* 0.000 description 2
125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
230000028993 immune response Effects 0.000 description 2
210000000987 immune system Anatomy 0.000 description 2
230000003053 immunization Effects 0.000 description 2
238000002649 immunization Methods 0.000 description 2
238000010324 immunological assay Methods 0.000 description 2
238000001114 immunoprecipitation Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
229910001410 inorganic ion Inorganic materials 0.000 description 2
239000003446 ligand Substances 0.000 description 2
206010025135 lupus erythematosus Diseases 0.000 description 2
229960005181 morphine Drugs 0.000 description 2
230000003071 parasitic effect Effects 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
239000004033 plastic Substances 0.000 description 2
229920003023 plastic Polymers 0.000 description 2
210000004910 pleural fluid Anatomy 0.000 description 2
229920001223 polyethylene glycol Polymers 0.000 description 2
229920002223 polystyrene Polymers 0.000 description 2
239000002244 precipitate Substances 0.000 description 2
239000000047 product Substances 0.000 description 2
238000003127 radioimmunoassay Methods 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
201000000306 sarcoidosis Diseases 0.000 description 2
238000009589 serological test Methods 0.000 description 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
230000003381 solubilizing effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
230000000087 stabilizing effect Effects 0.000 description 2
239000007785 strong electrolyte Substances 0.000 description 2
CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 2
229960002175 thyroglobulin Drugs 0.000 description 2
210000001685 thyroid gland Anatomy 0.000 description 2
230000001052 transient effect Effects 0.000 description 2
238000011282 treatment Methods 0.000 description 2
229940096911 trichinella spiralis Drugs 0.000 description 2
201000008827 tuberculosis Diseases 0.000 description 2
PROQIPRRNZUXQM-UHFFFAOYSA-N (16alpha,17betaOH)-Estra-1,3,5(10)-triene-3,16,17-triol Natural products OC1=CC=C2C3CCC(C)(C(C(O)C4)O)C4C3CCC2=C1 PROQIPRRNZUXQM-UHFFFAOYSA-N 0.000 description 1
NEVBYCDQGXFCCZ-UHFFFAOYSA-N 1-propylpyrido[2,3-d][1,3]oxazine-2,4-dione Chemical compound C1=CC=C2C(=O)OC(=O)N(CCC)C2=N1 NEVBYCDQGXFCCZ-UHFFFAOYSA-N 0.000 description 1
125000000022 2-aminoethyl group Chemical group [H]C([*])([H])C([H])([H])N([H])[H] 0.000 description 1
FEIQOMCWGDNMHM-UHFFFAOYSA-N 5-phenylpenta-2,4-dienoic acid Chemical compound OC(=O)C=CC=CC1=CC=CC=C1 FEIQOMCWGDNMHM-UHFFFAOYSA-N 0.000 description 1
208000030507 AIDS Diseases 0.000 description 1
241000186046 Actinomyces Species 0.000 description 1
241000186044 Actinomyces viscosus Species 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
VWEWCZSUWOEEFM-WDSKDSINSA-N Ala-Gly-Ala-Gly Chemical compound C[C@H](N)C(=O)NCC(=O)N[C@@H](C)C(=O)NCC(O)=O VWEWCZSUWOEEFM-WDSKDSINSA-N 0.000 description 1
208000035939 Alveolitis allergic Diseases 0.000 description 1
208000004881 Amebiasis Diseases 0.000 description 1
206010001935 American trypanosomiasis Diseases 0.000 description 1
241000428352 Amma Species 0.000 description 1
206010001980 Amoebiasis Diseases 0.000 description 1
102000004411 Antithrombin III Human genes 0.000 description 1
108090000935 Antithrombin III Proteins 0.000 description 1
206010003445 Ascites Diseases 0.000 description 1
241001507865 Aspergillus fischeri Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
241000271566 Aves Species 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
241000589562 Brucella Species 0.000 description 1
101150096672 CEL1 gene Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
241000589875 Campylobacter jejuni Species 0.000 description 1
241000701931 Canine parvovirus Species 0.000 description 1
241000282465 Canis Species 0.000 description 1
208000024699 Chagas disease Diseases 0.000 description 1
241000606161 Chlamydia Species 0.000 description 1
102000009016 Cholera Toxin Human genes 0.000 description 1
108010049048 Cholera Toxin Proteins 0.000 description 1
102000011022 Chorionic Gonadotropin Human genes 0.000 description 1
108010062540 Chorionic Gonadotropin Proteins 0.000 description 1
241000193163 Clostridioides difficile Species 0.000 description 1
208000035473 Communicable disease Diseases 0.000 description 1
108010028778 Complement C4 Proteins 0.000 description 1
208000019707 Cryoglobulinemic vasculitis Diseases 0.000 description 1
201000003808 Cystic echinococcosis Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
238000009007 Diagnostic Kit Methods 0.000 description 1
LTMHDMANZUZIPE-AMTYYWEZSA-N Digoxin Natural products O([C@H]1[C@H](C)O[C@H](O[C@@H]2C[C@@H]3[C@@](C)([C@@H]4[C@H]([C@]5(O)[C@](C)([C@H](O)C4)[C@H](C4=CC(=O)OC4)CC5)CC3)CC2)C[C@@H]1O)[C@H]1O[C@H](C)[C@@H](O[C@H]2O[C@@H](C)[C@H](O)[C@@H](O)C2)[C@@H](O)C1 LTMHDMANZUZIPE-AMTYYWEZSA-N 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
206010014096 Echinococciasis Diseases 0.000 description 1
208000009366 Echinococcosis Diseases 0.000 description 1
241000224431 Entamoeba Species 0.000 description 1
101710146739 Enterotoxin Proteins 0.000 description 1
241000709661 Enterovirus Species 0.000 description 1
241000283086 Equidae Species 0.000 description 1
208000027445 Farmer Lung Diseases 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
102000009123 Fibrin Human genes 0.000 description 1
108010073385 Fibrin Proteins 0.000 description 1
BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
102000016359 Fibronectins Human genes 0.000 description 1
108010067306 Fibronectins Proteins 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
241000287828 Gallus gallus Species 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
101710197836 HLA class I histocompatibility antigen, alpha chain G Proteins 0.000 description 1
102000014702 Haptoglobin Human genes 0.000 description 1
108050005077 Haptoglobin Proteins 0.000 description 1
102000001554 Hemoglobins Human genes 0.000 description 1
108010054147 Hemoglobins Proteins 0.000 description 1
241000709721 Hepatovirus A Species 0.000 description 1
208000003698 Heroin Dependence Diseases 0.000 description 1
241000228404 Histoplasma capsulatum Species 0.000 description 1
108010000521 Human Growth Hormone Proteins 0.000 description 1
102000002265 Human Growth Hormone Human genes 0.000 description 1
239000000854 Human Growth Hormone Substances 0.000 description 1
241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
241000726306 Irus Species 0.000 description 1
241000588748 Klebsiella Species 0.000 description 1
241000589248 Legionella Species 0.000 description 1
208000007764 Legionnaires' Disease Diseases 0.000 description 1
206010024238 Leptospirosis Diseases 0.000 description 1
102000004882 Lipase Human genes 0.000 description 1
108090001060 Lipase Proteins 0.000 description 1
239000004367 Lipase Substances 0.000 description 1
208000016604 Lyme disease Diseases 0.000 description 1
241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 1
201000005505 Measles Diseases 0.000 description 1
241000002163 Mesapamea fractilinea Species 0.000 description 1
241001529936 Murinae Species 0.000 description 1
241000186359 Mycobacterium Species 0.000 description 1
241000187479 Mycobacterium tuberculosis Species 0.000 description 1
206010028470 Mycoplasma infections Diseases 0.000 description 1
241000202934 Mycoplasma pneumoniae Species 0.000 description 1
102100030856 Myoglobin Human genes 0.000 description 1
108010062374 Myoglobin Proteins 0.000 description 1
AXDLCFOOGCNDST-UHFFFAOYSA-N N-methyl-DL-tyrosine Natural products CNC(C(O)=O)CC1=CC=C(O)C=C1 AXDLCFOOGCNDST-UHFFFAOYSA-N 0.000 description 1
241000588652 Neisseria gonorrhoeae Species 0.000 description 1
241000588650 Neisseria meningitidis Species 0.000 description 1
239000004677 Nylon Substances 0.000 description 1
206010033546 Pallor Diseases 0.000 description 1
208000030852 Parasitic disease Diseases 0.000 description 1
101000882917 Penaeus paulensis Hemolymph clottable protein Proteins 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
102000035195 Peptidases Human genes 0.000 description 1
201000005702 Pertussis Diseases 0.000 description 1
CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 description 1
206010035148 Plague Diseases 0.000 description 1
102000013566 Plasminogen Human genes 0.000 description 1
108010051456 Plasminogen Proteins 0.000 description 1
208000035109 Pneumococcal Infections Diseases 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
206010036790 Productive cough Diseases 0.000 description 1
241000588769 Proteus <enterobacteria> Species 0.000 description 1
241000589516 Pseudomonas Species 0.000 description 1
241000606699 Rickettsia conorii Species 0.000 description 1
241000606697 Rickettsia prowazekii Species 0.000 description 1
241000606726 Rickettsia typhi Species 0.000 description 1
241000606651 Rickettsiales Species 0.000 description 1
208000006257 Rinderpest Diseases 0.000 description 1
206010039710 Scleroderma Diseases 0.000 description 1
229920005654 Sephadex Polymers 0.000 description 1
239000012507 Sephadex™ Substances 0.000 description 1
102000005686 Serum Globulins Human genes 0.000 description 1
108010045362 Serum Globulins Proteins 0.000 description 1
241000607768 Shigella Species 0.000 description 1
208000021386 Sjogren Syndrome Diseases 0.000 description 1
241000193998 Streptococcus pneumoniae Species 0.000 description 1
239000002174 Styrene-butadiene Substances 0.000 description 1
206010042276 Subacute endocarditis Diseases 0.000 description 1
241000282890 Sus Species 0.000 description 1
241000282898 Sus scrofa Species 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
102000009843 Thyroglobulin Human genes 0.000 description 1
108010034949 Thyroglobulin Proteins 0.000 description 1
241000223997 Toxoplasma gondii Species 0.000 description 1
201000005485 Toxoplasmosis Diseases 0.000 description 1
241000224526 Trichomonas Species 0.000 description 1
241000223104 Trypanosoma Species 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
208000034784 Tularaemia Diseases 0.000 description 1
208000036142 Viral infection Diseases 0.000 description 1
206010047505 Visceral leishmaniasis Diseases 0.000 description 1
229930003448 Vitamin K Natural products 0.000 description 1
108091093126 WHP Posttrascriptional Response Element Proteins 0.000 description 1
241000244005 Wuchereria bancrofti Species 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000009471 action Effects 0.000 description 1
230000004913 activation Effects 0.000 description 1
231100000354 acute hepatitis Toxicity 0.000 description 1
239000008272 agar Substances 0.000 description 1
230000004931 aggregating effect Effects 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
125000000217 alkyl group Chemical group 0.000 description 1
108010050122 alpha 1-Antitrypsin Proteins 0.000 description 1
102000015395 alpha 1-Antitrypsin Human genes 0.000 description 1
229940024142 alpha 1-antitrypsin Drugs 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000003321 amplification Effects 0.000 description 1
210000004102 animal cell Anatomy 0.000 description 1
150000001449 anionic compounds Chemical class 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003171 anti-complementary effect Effects 0.000 description 1
230000003460 anti-nuclear Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
230000005875 antibody response Effects 0.000 description 1
238000009175 antibody therapy Methods 0.000 description 1
230000007503 antigenic stimulation Effects 0.000 description 1
229960005348 antithrombin iii Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007864 aqueous solution Substances 0.000 description 1
210000003567 ascitic fluid Anatomy 0.000 description 1
238000003149 assay kit Methods 0.000 description 1
230000002238 attenuated effect Effects 0.000 description 1
210000003719 b-lymphocyte Anatomy 0.000 description 1
HNYOPLTXPVRDBG-UHFFFAOYSA-M barbiturate Chemical compound O=C1CC(=O)[N-]C(=O)N1 HNYOPLTXPVRDBG-UHFFFAOYSA-M 0.000 description 1
239000002981 blocking agent Substances 0.000 description 1
238000009640 blood culture Methods 0.000 description 1
210000001772 blood platelet Anatomy 0.000 description 1
MTAZNLWOLGHBHU-UHFFFAOYSA-N butadiene-styrene rubber Chemical compound C=CC=C.C=CC1=CC=CC=C1 MTAZNLWOLGHBHU-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
239000000679 carrageenan Substances 0.000 description 1
229920001525 carrageenan Polymers 0.000 description 1
229940113118 carrageenan Drugs 0.000 description 1
235000010418 carrageenan Nutrition 0.000 description 1
238000000423 cell based assay Methods 0.000 description 1
230000022534 cell killing Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
238000004587 chromatography analysis Methods 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
238000000576 coating method Methods 0.000 description 1
230000009137 competitive binding Effects 0.000 description 1
230000002860 competitive effect Effects 0.000 description 1
230000000536 complexating effect Effects 0.000 description 1
238000012790 confirmation Methods 0.000 description 1
208000018631 connective tissue disease Diseases 0.000 description 1
239000000470 constituent Substances 0.000 description 1
239000013068 control sample Substances 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
201000003278 cryoglobulinemia Diseases 0.000 description 1
210000004292 cytoskeleton Anatomy 0.000 description 1
230000003247 decreasing effect Effects 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000014670 detection of bacterium Effects 0.000 description 1
230000010460 detection of virus Effects 0.000 description 1
238000010586 diagram Methods 0.000 description 1
LEOJDCQCOZOLTQ-UHFFFAOYSA-N dibutylcarbamothioyl n,n-dibutylcarbamodithioate Chemical compound CCCCN(CCCC)C(=S)SC(=S)N(CCCC)CCCC LEOJDCQCOZOLTQ-UHFFFAOYSA-N 0.000 description 1
229960005156 digoxin Drugs 0.000 description 1
MOAVUYWYFFCBNM-PUGKRICDSA-N digoxin(1-) Chemical compound C[C@H]([C@H]([C@H](C1)O)O)O[C@H]1O[C@H]([C@@H](C)O[C@H](C1)O[C@H]([C@@H](C)O[C@H](C2)O[C@@H](CC3)C[C@@H](CC4)[C@@]3(C)[C@@H](C[C@H]([C@]3(C)[C@H](CC5)C([CH-]O6)=CC6=O)O)[C@@H]4[C@]35O)[C@H]2O)[C@H]1O MOAVUYWYFFCBNM-PUGKRICDSA-N 0.000 description 1
LTMHDMANZUZIPE-UHFFFAOYSA-N digoxine Natural products C1C(O)C(O)C(C)OC1OC1C(C)OC(OC2C(OC(OC3CC4C(C5C(C6(CCC(C6(C)C(O)C5)C=5COC(=O)C=5)O)CC4)(C)CC3)CC2O)C)CC1O LTMHDMANZUZIPE-UHFFFAOYSA-N 0.000 description 1
VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
206010013663 drug dependence Diseases 0.000 description 1
239000012636 effector Substances 0.000 description 1
230000009881 electrostatic interaction Effects 0.000 description 1
238000005421 electrostatic potential Methods 0.000 description 1
208000006036 elephantiasis Diseases 0.000 description 1
201000002491 encephalomyelitis Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
239000000147 enterotoxin Substances 0.000 description 1
231100000655 enterotoxin Toxicity 0.000 description 1
230000002255 enzymatic effect Effects 0.000 description 1
229960001348 estriol Drugs 0.000 description 1
229940011871 estrogen Drugs 0.000 description 1
239000000262 estrogen Substances 0.000 description 1
BEGBSFPALGFMJI-UHFFFAOYSA-N ethene;sodium Chemical group [Na].C=C BEGBSFPALGFMJI-UHFFFAOYSA-N 0.000 description 1
239000000284 extract Substances 0.000 description 1
208000022195 farmer lung disease Diseases 0.000 description 1
239000012894 fetal calf serum Substances 0.000 description 1
239000000835 fiber Substances 0.000 description 1
229950003499 fibrin Drugs 0.000 description 1
230000003311 flocculating effect Effects 0.000 description 1
239000007850 fluorescent dye Substances 0.000 description 1
238000005194 fractionation Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
229960002518 gentamicin Drugs 0.000 description 1
208000005252 hepatitis A Diseases 0.000 description 1
229960001340 histamine Drugs 0.000 description 1
229940084986 human chorionic gonadotropin Drugs 0.000 description 1
229960000890 hydrocortisone Drugs 0.000 description 1
230000008105 immune reaction Effects 0.000 description 1
230000000951 immunodiffusion Effects 0.000 description 1
238000000760 immunoelectrophoresis Methods 0.000 description 1
239000003547 immunosorbent Substances 0.000 description 1
238000000338 in vitro Methods 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
201000006747 infectious mononucleosis Diseases 0.000 description 1
238000005304 joining Methods 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
238000000670 ligand binding assay Methods 0.000 description 1
235000019421 lipase Nutrition 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
208000019423 liver disease Diseases 0.000 description 1
230000004807 localization Effects 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
210000002540 macrophage Anatomy 0.000 description 1
201000004792 malaria Diseases 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
239000000463 material Substances 0.000 description 1
239000012528 membrane Substances 0.000 description 1
239000012982 microporous membrane Substances 0.000 description 1
210000003470 mitochondria Anatomy 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
238000012544 monitoring process Methods 0.000 description 1
210000001616 monocyte Anatomy 0.000 description 1
NAFSTSRULRIERK-UHFFFAOYSA-M monosodium urate Chemical class [Na+].N1C([O-])=NC(=O)C2=C1NC(=O)N2 NAFSTSRULRIERK-UHFFFAOYSA-M 0.000 description 1
201000006417 multiple sclerosis Diseases 0.000 description 1
238000004848 nephelometry Methods 0.000 description 1
229960000808 netilmicin Drugs 0.000 description 1
ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
230000036963 noncompetitive effect Effects 0.000 description 1
238000003199 nucleic acid amplification method Methods 0.000 description 1
210000004287 null lymphocyte Anatomy 0.000 description 1
229920001778 nylon Polymers 0.000 description 1
QYSGYZVSCZSLHT-UHFFFAOYSA-N octafluoropropane Chemical compound FC(F)(F)C(F)(F)C(F)(F)F QYSGYZVSCZSLHT-UHFFFAOYSA-N 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
150000002891 organic anions Chemical class 0.000 description 1
125000004430 oxygen atom Chemical group O* 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000037361 pathway Effects 0.000 description 1
DDBREPKUVSBGFI-UHFFFAOYSA-N phenobarbital Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NC(=O)NC1=O DDBREPKUVSBGFI-UHFFFAOYSA-N 0.000 description 1
229960002695 phenobarbital Drugs 0.000 description 1
229960002036 phenytoin Drugs 0.000 description 1
239000008363 phosphate buffer Substances 0.000 description 1
150000003904 phospholipids Chemical class 0.000 description 1
SHUZOJHMOBOZST-UHFFFAOYSA-N phylloquinone Natural products CC(C)CCCCC(C)CCC(C)CCCC(=CCC1=C(C)C(=O)c2ccccc2C1=O)C SHUZOJHMOBOZST-UHFFFAOYSA-N 0.000 description 1
230000004962 physiological condition Effects 0.000 description 1
229940012957 plasmin Drugs 0.000 description 1
208000005987 polymyositis Diseases 0.000 description 1
239000004800 polyvinyl chloride Substances 0.000 description 1
229920000915 polyvinyl chloride Polymers 0.000 description 1
229920002102 polyvinyl toluene Polymers 0.000 description 1
238000011533 pre-incubation Methods 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002335 preservative effect Effects 0.000 description 1
150000003140 primary amides Chemical class 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
229960002393 primidone Drugs 0.000 description 1
DQMZLTXERSFNPB-UHFFFAOYSA-N primidone Chemical compound C=1C=CC=CC=1C1(CC)C(=O)NCNC1=O DQMZLTXERSFNPB-UHFFFAOYSA-N 0.000 description 1
230000006916 protein interaction Effects 0.000 description 1
208000009305 pseudorabies Diseases 0.000 description 1
238000000275 quality assurance Methods 0.000 description 1
238000012113 quantitative test Methods 0.000 description 1
239000000700 radioactive tracer Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
230000001105 regulatory effect Effects 0.000 description 1
230000012423 response to bacterium Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
238000012552 review Methods 0.000 description 1
238000010850 salt effect Methods 0.000 description 1
239000012266 salt solution Substances 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
125000000467 secondary amino group Chemical group [H]N([*:1])[*:2] 0.000 description 1
210000000582 semen Anatomy 0.000 description 1
229940076279 serotonin Drugs 0.000 description 1
238000001542 size-exclusion chromatography Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000009518 sodium iodide Nutrition 0.000 description 1
238000002764 solid phase assay Methods 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
238000001179 sorption measurement Methods 0.000 description 1
238000007811 spectroscopic assay Methods 0.000 description 1
210000003802 sputum Anatomy 0.000 description 1
208000024794 sputum Diseases 0.000 description 1
229940031000 streptococcus pneumoniae Drugs 0.000 description 1
229960005202 streptokinase Drugs 0.000 description 1
239000011115 styrene butadiene Substances 0.000 description 1
229920003048 styrene butadiene rubber Polymers 0.000 description 1
208000008467 subacute bacterial endocarditis Diseases 0.000 description 1
FIAFUQMPZJWCLV-UHFFFAOYSA-N suramin Chemical compound OS(=O)(=O)C1=CC(S(O)(=O)=O)=C2C(NC(=O)C3=CC=C(C(=C3)NC(=O)C=3C=C(NC(=O)NC=4C=C(C=CC=4)C(=O)NC=4C(=CC=C(C=4)C(=O)NC=4C5=C(C=C(C=C5C(=CC=4)S(O)(=O)=O)S(O)(=O)=O)S(O)(=O)=O)C)C=CC=3)C)=CC=C(S(O)(=O)=O)C2=C1 FIAFUQMPZJWCLV-UHFFFAOYSA-N 0.000 description 1
229960005314 suramin Drugs 0.000 description 1
210000001179 synovial fluid Anatomy 0.000 description 1
238000003786 synthesis reaction Methods 0.000 description 1
201000000596 systemic lupus erythematosus Diseases 0.000 description 1
150000003511 tertiary amides Chemical class 0.000 description 1
125000001302 tertiary amino group Chemical group 0.000 description 1
229960000814 tetanus toxoid Drugs 0.000 description 1
KSYNLCYTMRMCGG-UHFFFAOYSA-J tetrasodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;dihydrate Chemical compound O.O.[Na+].[Na+].[Na+].[Na+].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O KSYNLCYTMRMCGG-UHFFFAOYSA-J 0.000 description 1
238000010257 thawing Methods 0.000 description 1
229960000278 theophylline Drugs 0.000 description 1
125000003396 thiol group Chemical group [H]S* 0.000 description 1
206010043778 thyroiditis Diseases 0.000 description 1
229960000707 tobramycin Drugs 0.000 description 1
NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
201000002311 trypanosomiasis Diseases 0.000 description 1
239000012588 trypsin Substances 0.000 description 1
238000004879 turbidimetry Methods 0.000 description 1
238000002255 vaccination Methods 0.000 description 1
230000009385 viral infection Effects 0.000 description 1
235000019168 vitamin K Nutrition 0.000 description 1
239000011712 vitamin K Substances 0.000 description 1
150000003721 vitamin K derivatives Chemical class 0.000 description 1
229940046010 vitamin k Drugs 0.000 description 1
108010047303 von Willebrand Factor Proteins 0.000 description 1
102100036537 von Willebrand factor Human genes 0.000 description 1
229960001134 von willebrand factor Drugs 0.000 description 1
230000003313 weakening effect Effects 0.000 description 1
201000009482 yaws Diseases 0.000 description 1
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1

Classifications

- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/5306—Improving reaction conditions, e.g. reduction of non-specific binding, promotion of specific binding
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/10—Musculoskeletal or connective tissue disorders
- G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
- G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Chemical & Material Sciences (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Molecular Biology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Cell Biology (AREA)
Pathology (AREA)
Food Science & Technology (AREA)
Medicinal Chemistry (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
General Physics & Mathematics (AREA)
Chemical Kinetics & Catalysis (AREA)
Rehabilitation Therapy (AREA)
Rheumatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

CA 2110159 1992-03-26 1993-03-26 Technique permettant de prevenir les fausses reactions dans les tests immunologiques Abandoned CA2110159A1 (fr)

Applications Claiming Priority (6)

Application Number	Priority Date	Filing Date
US85776592A	1992-03-26	1992-03-26
US85776492A	1992-03-26	1992-03-26
US07/857,764		1992-03-26
US07/857,765		1992-03-26
US1454993A	1993-02-08	1993-02-08
US08/014,549		1993-02-08

Publications (1)

Publication Number	Publication Date
CA2110159A1 true CA2110159A1 (fr)	1993-09-30

Family

ID=27360128

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA 2110159 Abandoned CA2110159A1 (fr)	1992-03-26	1993-03-26	Technique permettant de prevenir les fausses reactions dans les tests immunologiques

Country Status (5)

Country	Link
EP (1)	EP0586693A4 (fr)
JP (1)	JPH07500190A (fr)
AU (1)	AU3969393A (fr)
CA (1)	CA2110159A1 (fr)
WO (1)	WO1993019369A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2987836A1 (fr) *	2012-03-09	2013-09-13	Biomerieux Sa	Peptides d'interference et procede de detection de microorganismes

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB1508132A (en) *	1974-05-20	1978-04-19	Technicon Instr	Analysis of biological fluids
US4379085A (en) *	1982-05-14	1983-04-05	American National Red Cross	Heat stabilization of plasma proteins

1993
- 1993-03-26 JP JP5516856A patent/JPH07500190A/ja active Pending
- 1993-03-26 AU AU39693/93A patent/AU3969393A/en not_active Abandoned
- 1993-03-26 EP EP93909191A patent/EP0586693A4/fr not_active Withdrawn
- 1993-03-26 WO PCT/US1993/002901 patent/WO1993019369A1/fr not_active Ceased
- 1993-03-26 CA CA 2110159 patent/CA2110159A1/fr not_active Abandoned

Also Published As

Publication number	Publication date
JPH07500190A (ja)	1995-01-05
WO1993019369A1 (fr)	1993-09-30
AU3969393A (en)	1993-10-21
EP0586693A4 (fr)	1995-01-25
EP0586693A1 (fr)	1994-03-16

Legal Events

Date	Code	Title	Description
1998-03-26	FZDE	Dead

Publication	Publication Date	Title
US4332783A (en)	1982-06-01	Process for immunologic determination tests
Cambiaso et al.	1977	Particle counting immunoassay (PACIA). I. A general method for the determination of antibodies, antigens, and haptens
US4680274A (en)	1987-07-14	Particles for inhibiting non-specific immunoreaction
EP0124352A2 (fr)	1984-11-07	Essai protégé de liaison
JPS5915860A (ja)	1984-01-26	抗体、抗原または抗体：抗原複合体の分析法
EP0223843A4 (fr)	1989-06-21	Procede et element de detection de composes immunitaires.
US4427781A (en)	1984-01-24	Particle agglutination immunoassay with agglutinator for determining haptens; PACIA
US4299815A (en)	1981-11-10	Carcinoembryonic antigen determination
JP2001502795A (ja)	2001-02-27	血液型抗原および抗体の検出に有用な方法および装置
US4210622A (en)	1980-07-01	Kit for assay of immune complexes
EP0101166B1 (fr)	1987-08-26	Procédé pour le dosage d'anticorps d'une maladie infectieuse
US4753893A (en)	1988-06-28	Method and article for detection of immune complexes
US5843794A (en)	1998-12-01	Technique for the prevention of false positive reactions in immunological testing due to C1 and C1q components of the complement and method for screening for rheumatic factor
JPH0220068B2 (fr)	1990-05-08
JPH01129163A (ja)	1989-05-22	アポリポタンパク質ｂの診断試薬および測定法
CA2088404C (fr)	2004-06-22	Methode de determination des antigenes ou des anticorps en presence d'un complexe immun
CA2110159A1 (fr)	1993-09-30	Technique permettant de prevenir les fausses reactions dans les tests immunologiques
US5637472A (en)	1997-06-10	Hydrazine derivatized cells
JPH05203642A (ja)	1993-08-10	ベックマン比濁計システムへの使用のための新規抗ストレプトリジン−ｏ試薬
JPH08327629A (ja)	1996-12-13	検体前処理方法
US5288610A (en)	1994-02-22	Detecting reagent for antiplatelet antibody
Osborne et al.	1980	Enzyme-linked immunosorbent assay for the indirect anti-human globulin test
Sanderson	1971	The detection of antibody and demonstration of immunoglobulin class, with inert particles and indicator red cells
JPH08193999A (ja)	1996-07-30	免疫測定法
KATO	1984	Quantitation of red-cell-bound IgG in normal and pathologic states by an enzyme immunoassay (EIA) technique